GSK Says Cancer Medicine Cleared by EU Meets Another Study Goal

GSK Plc’s Jemperli extended the lives of patients with endometrial cancer in the second part of a late-stage test, results that come a week after the medicine won clearance in the European Union.

Jemperli, when combined with chemotherapy first and then GSK’s other cancer drug Zejula as maintenance therapy, showed a “statistically significant and clinically meaningful benefit,” the company said without releasing more trial details.